Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer

Chen,Jiong; Wu,Wen; Zhen,Chunsheng; Zhou,Hangchen; Yang,Renbao; Chen,Longjiang; Hu,Liwei

doi:10.3892/ol.2013.1326

Expression and clinical significance of complement C3, complement C4b1 and apolipoprotein E in pancreatic cancer

Authors:
- Jiong Chen
- Wen Wu
- Chunsheng Zhen
- Hangchen Zhou
- Renbao Yang
- Longjiang Chen
- Liwei Hu
View Affiliations

Affiliations: Department of General Surgery, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, P.R. China
Published online on: April 30, 2013 https://doi.org/10.3892/ol.2013.1326
Pages: 43-48

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer (PC) remains a devastating disease with a five‑year survival rate of <5%. The difficulty in making an early diagnosis and the frequent occurrence of metastasis are important reasons for this poor prognosis. In China, the incidence of PC has been increasing steadily. Therefore, the present study aimed to identify effective markers in the early and advanced stages of PC. The expression levels of complement C3, complement C4b1 and apolipoprotein E (ApoE) in the various stages of PC were assessed by immunohistochemistry, RT‑PCR and western blotting. Additionally, the statistical significance of the results was analyzed. The expression levels of complement C3, complement C4b1 and apoE were higher in PC compared with normal pancreatic tissues. No correlations were observed between complement C3 and tumor TNM staging or lymph node metastasis. However, complement C4b1 and apoE were markedly correlated with tumor TNM staging and lymph node metastasis. Complement C3 may be used as a marker for the diagnosis of early‑stage PC, while complement C4b1 and apoE are closely correlated with tumor development, reflecting the biological behavior of PC, and thus may be used as diagnostic markers of advanced PC.

View Figures

View References

1.	Guo X and Cui Z: Current diagnosis and treatment of pancreatic cancer in China. Pancreas. 31:13–22. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Willett CG, Daly WJ and Warshaw AL: CA 19–9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg. 172:350–352. 1996.
3.	Goonetilleke KS and Siriwardena AK: Systematic review of carbohydrate antigen (CA 19–9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 33:266–270. 2007.PubMed/NCBI
4.	Marrelli D, Caruso S, Pedrazzani C, et al: CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 198:333–339. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Grønborg M, Bunkenborg J, Kristiansen TZ, et al: Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res. 3:1042–1055. 2004.
6.	Cecconi D, Palmieri M and Donadelli M: Proteomics in pancreatic cancer research. Proteomics. 11:816–828. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Hugli TE: Structure and function of the anaphylatoxins. Springer Semin Immunopathol. 7:193–219. 1984. View Article : Google Scholar : PubMed/NCBI
8.	Scholz W, McClurg MR, Cardenas GJ, et al: C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol. 57:297–307. 1990. View Article : Google Scholar : PubMed/NCBI
9.	Wang W, Abbruzzese JL, Evans DB, et al: The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 5:119–127. 1999.PubMed/NCBI
10.	Habermann JK, Roblick UJ, Luke BT, et al: Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology. 131:1020–1029. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Pickering MC, Botto M, Taylor PR, et al: Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol. 76:227–324. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Einav S, Pozdnyakova OO, Ma M and Carroll MC: Complement C4 is protective for lupus disease independent of C3. J Immunol. 168:1036–1041. 2002. View Article : Google Scholar : PubMed/NCBI
13.	Fujita T, Hara A and Yamazaki Y: The value of acute-phase protein measurements after curative gastric cancer surgery. Arch Surg. 134:73–75. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Greenow K, Pearce NJ and Ramji DP: The key role of apolipoprotein E in atherosclerosis. J Mol Med (Berl). 83:329–342. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Trompet S, Jukema JW, Katan MB, et al: Apolipoprotein e genotype, plasma cholesterol, and cancer: a Mendelian randomization study. Am J Epidemiol. 170:1415–1421. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Trost Z, Marc J, Sok M and Cerne D: Increased apolipoprotein E gene expression and protein concentration in lung cancer tissue do not contribute to the clinical assessment of non-small cell lung cancer patients. Arch Med Res. 39:663–667. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Grant WB: A multicountry ecological study of risk-modifying factors for prostate cancer: apolipoprotein E epsilon4 as a risk factor and cereals as a risk reduction factor. Anticancer Res. 30:189–199. 2010.PubMed/NCBI
18.	Andreotti G, Chen J, Gao YT, et al: Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 17:525–534. 2008. View Article : Google Scholar : PubMed/NCBI
19.	Moore LE, Brennan P, Karami S, et al: Apolipoprotein E/C1 locus variants modify renal cell carcinoma risk. Cancer Res. 69:8001–8008. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Beppu T, Gil-Bernabe P, Boveda-Ruiz D, et al: High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double-deficient mice. J Tromb Haemost. 8:2514–2522. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Mrkonjic M, Chappell E, Pethe VV, et al: Association of apolipoprotein E polymorphisms and dietary factors in colorectal cancer. Br J Cancer. 100:1966–1974. 2009. View Article : Google Scholar : PubMed/NCBI
22.	Grønborg M, Kristiansen TZ, Iwahori A, et al: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics. 5:157–171. 2006.PubMed/NCBI
23.	Yu KH, Rustgi AK and Blair IA: Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res. 4:1742–1751. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Gillard BK, Lin HY, Massey JB and Pownall HJ: Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. Biochim Biophys Acta. 1791:1125–1132. 2009. View Article : Google Scholar : PubMed/NCBI
25.	Huvila J, Brandt A, Rojas CR, et al: Gene expression profiling of endometrial adenocarcinomas reveals increased apolipoprotein E expression in poorly differentiated tumors. Int J Gynecol Cancer. 19:1226–1231. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Martínez-Clemente M, Ferré N, González-Périz A, et al: 5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology. 51:817–827. 2010.PubMed/NCBI